Table 2.

Clinical outcomes

Variables	Dalbavancin (n = 12)	SOC (n = 263)	p value
Primary outcome
Total direct costs, US$ per patient	$2758	$4010	0.105
Secondary outcomes
Total indirect cost, US$ per patient	$2913	$3646	0.162
Baseline serum creatinine, mg/dL	0.8 [0.7–1]	0.9 [0.7–1]	0.640
Acute kidney injury	0 (0)	33 (12.6)	0.371
Hospital acquired infection	0 (0)	2 (0.8)	1.000
Documented infusion reaction	0 (0)	4 (1.5)	1.000
Median length of stay, days	4 [2.8–4.3]	4 [2–6]	0.888
30-day readmission rate	1 (8.3%)	19 (7.2%)	0.604

Data are presented as n (%) or median [IQR]